Ceretype Neuromedicine, Inc.
United States
- Cambridge, MA
- 05/01/2024
- Seed
- Undisclosed Amount
Ceretype has pioneered the integration of fMRI into therapeutic applications in neuropsychiatry. Our uniquely scalable platform makes targeted biomarkers accessible, delivering actionable insights for our pharma/biotech partners. Our decades of expertise across neuromedicine, brain imaging, and industry processes enables innovations that will ultimately transform patient care.
- Industry Biotechnology
- Website https://ceretype.com/
- LinkedIn https://www.linkedin.com/company/ceretype/about/
Related People
Emily SternCo Founder
United States -
Cambridge, Massachusetts
I am the CEO and Co-founder of Ceretype Neuromedicine, a radiologist, neuroscience researcher and expert in psychiatric neuroimaging, with significant, broad leadership and management experience. My passion for improving the lives of patients with neuropsychiatric disorders using biologically-based tools has led to the translation of my lab's innovative and novel academic work into clinically useful solutions via Ceretype Neuromedicine, Inc. I have led company spin-out (from Brigham and Women's Hospital/Harvard Medical School) and development, including defining strategic vision, business model development, intellectual property portfolio creation (2 patents issued, 2 pending), licensing, fund-raising, client engagement, and project development/implementation. I am a collaborative leader with exceptional communication skills.
Previously, I have directed top neuroimaging research laboratories at Weill Cornell Medical College and Brigham and Women’s Hospital (BWH)/Harvard Medical School for a total of 25 years, initiating and overseeing multiple interdisciplinary scientific projects (15 as Principal, Co-Principal or Site Principal Investigator), many funded through the NIH. As Director of Functional and Molecular Neuroimaging, I built the programmatic and physical infrastructure for fMRI at BWH, including directing a $13M building project (obtained and directed the execution of a $6M NIH grant). I have significant experience leading complex and multisite projects, including obtaining funding (including grant applications), study design, methods development, study approvals, study implementation, personnel training and management, quality control, neurobiological/functional neuroanatomic data interpretation, study reporting, and abstract and manuscript preparation.
In addition, I have served on multiple committees to advance the academic mission at both Weill Cornell and BWH/HMS, including Co-chairing the Brigham Research Institute’s Neuroscience Research Center for 8 years. I am an experienced grant and manuscript reviewer, have served on editorial boards and am a seasoned educator and mentor, having developed curricula and taught in multiple venues (including in the context of an NIH R25 Educational Grant [Co-Prinicipal Investigator]).
Forage | $40,000,000 | (Jun 5, 2026)
InCharge Energy | $46,000,000 | (Jun 5, 2026)
Oak Hill Bio | $32,500,000 | (Jun 5, 2026)
ZutaCore | $100,000,000 | (Jun 5, 2026)
Terra AI | $20,000,000 | (Jun 5, 2026)
Town | $55,000,000 | (Jun 5, 2026)
Lassie | $35,000,000 | (Jun 5, 2026)
OFFROAD | $7,000,000 | (Jun 5, 2026)
Shifters | $10,200,000 | (Jun 5, 2026)
Quobly | $133,545,475 | (Jun 5, 2026)
Scispot | $8,000,000 | (Jun 5, 2026)
Scotch | $20,000,000 | (Jun 5, 2026)